Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193700 | 0.92 | MMP1 (0.41) | GHSROPRK1MMP2PLG | |
| SCHEMBL2183063 | 0.91 | MMP2 (0.43) | GHSROPRK1MMP2PSMB1PSMB8 | |
| SCHEMBL9391225 | 0.89 | ERAP2 (0.49) | GHSROPRK1MMP2PSMB1PSMB8 | |
| SCHEMBL11209585 | 0.89 | MMP2 (0.33) | GHSRCTSCMMP2 | |
| SCHEMBL9523924 | 0.89 | MMP2 (0.33) | GHSRCTSCMMP2 | |
| SCHEMBL2196425 | 0.88 | PSMB1 (0.41) | GHSROPRK1CTSCMMP2PSMB1 | |
| SCHEMBL9747710 | 0.87 | ERAP2 (0.47) | GHSROPRK1MMP2PSMB1PSMB8 | |
| SCHEMBL9747696 | 0.87 | ERAP2 (0.47) | GHSROPRK1MMP2PSMB1PSMB8 | |
| SCHEMBL29531327 | 0.87 | ERAP2 (0.47) | GHSROPRK1MMP2PSMB1PSMB8 | |
| SCHEMBL9394146 | 0.86 | GHSR (0.48) | GHSROPRK1PSMB1PSMB8PSMB9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | GHSR 1894/4885OPRK1 2737/4885CTSC 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.